† Footnotes relating to the title and/or authors should appear here. Electronic Supplementary Information (ESI) available: X-ray diffraction patterns, small-angle X-ray scattering curves and evaluated parameters, additional FTinfrared spectra and size distribution functions. Porous, fluorescent zirconia particles of nearly 380 nm diameter were prepared without template molecule or labeling dye. The porous structure is the result of aggregation-induced particle formation. The inherent fluorescence is assigned to coordinatively unsaturated Zr 4+ ions at the sol-gel derived ZrO2 surface. After physico-chemical characterization of the native zirconia particles carboxyl and/or amine bearing drug molecules (D,L-α-difluoromethylornithine -DFMO, ursolic acid -UA and doxorubicin -DOX) were adsorbed onto their surface, and the products were analyzed with Fouriertransform infrared spectroscopy (FTIR), thermogravimetry (TG), small-angle X-ray scattering (SAXS), fluorimetry and zeta potential vs. pH measurements. We have found that DOX complexes coordinatively unsaturated Zr 4+ ions without dislocating them, while carboxyl-bearing drugs interact with basic surface Zr-OH sites eliminating some of the carbonate species. The adsorption of UA at the zirconia surface shifts considerably the isoelectic point of the surface and thus provides kinetic stability to the particles at physiological pH. In vivo biodistribution study in two healthy dogs performed by SPECT/CT detection after 99m Tc labeling of the nanocarriers has shown the possibility of drug delivery application.
Introduction
Nano-and microparticles of various kinds are currently investigated with the prospect of drug delivery application. The requirements to be fulfilled are numerous: drug carrier particles should encapsulate, transport and release drug molecules in a controlled way in living organism 1 . Multifunctionality is, therefore, inevitable and -when coupled to easy synthesis -represents a great advantage. Among inorganic particles silica 2, 3 is preferred for its controlled synthesis, low toxicity, established conjugation methods and high drug loading capacity (for mesoporous silica). Zirconia, a ceramic material is used for biomedical applications e.g. in dental and chirurgical implants [4] [5] [6] . It is known to be biocompatible, and we have shown in our preliminary experiments that zirconia is also biodegradable under certain circumstances. The surface of zirconia is chemically active, having both acidic and basic sites 7 . This explains that zirconia chemisorbs both NH 3 and CO 2 8 . Under ambient, zirconia surface is always covered by adsorbed CO and CO 2 from the air 9, 10 . Complex formation has also been observed with the carboxyl groups of citric acid and poly-ε-caprolactone 11, 12 . As it was observed by Pokrovsky et al. CO 2 adsorption on monoclinic (m-) ZrO 2 is more than an order of magnitude higher than that on tetragonal (t-) ZrO 2
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. High-temperature synthesis or annealing of ZrO 2 leads to the transformation of monoclinic phase into tetragonal. However, the lack of generally approved synthetic method providing stable m-ZrO 2 colloid hinders its use as a drug carrier. Nanocrystalline powders of t-ZrO 2 are produced by aqueous phase reaction followed by annealing [14] [15] [16] [17] . These materials sintered by a final annealing cannot be suspended to yield a stable uniform colloid. Spherical m-ZrO 2 is obtained from alkoxide precursors in alcohol after controlled hydrolysis and condensation [18] [19] [20] . The diameter of these particles is usually over micrometer, and could only be reduced down to 200 nm by the addition of monovalent metallic cations 20 . For nano-sized object, the use of a template is necessary 21, 22 , however, this involves multi-step preparation.
In this paper we investigated the possibility of obtaining multifunctional: porous and fluorescent zirconia particles in one single synthetic step that are able to adsorb significant quantity of drug. We intended to induce both porosity and fluorescence in ZrO 2 starting from the method of Widoniak et al. 20 where these functionalities were not described. Zhang and coworkers described cetyl trimethylammonium bromide (CTAB) induced fluorescence in ZrO 2 powders 23 . Surfactant was eliminated in both procedures by annealing that we wished to avoid. We carried out preliminary experiments with CTAB templating as well, and tried to eliminate the surfactant by excessive washing. The structure and fluorescence of the obtained materials is compared and discussed in this paper. Finally, the affinity of the obtained zirconia particles towards carboxyl and/or amine bearing drug molecules was studied. For this study, three anticancer drug molecules were chosen: D,L-α-difluoromethylornithine (DFMO, also known as eflornithine), doxorubicin (DOX) and ursolic acid (UA). There is a significant difference between them in several aspects: structure, solubility, acidity (Table 1) . In short, DFMO is a highly water soluble, nontoxic small molecule, whose main disadvantage is its rapid clearance from the body, therefore its clinical use for cancer treatment was stopped. DOX is a cardiotoxic drug, whose nanoformulated products are proven to be more efficient and less harmful than its free form 30 . UA is a natural anticancer compound 31, 32 , whose very low water solubility prevents its use in pharmaceutics 27 . The structure of drug loaded ZrO 2 particles was examined with SAXS in the present work. The affinity of DFMO, DOX and UA towards zirconia surface was investigated using TG, zeta potential-pH curves, and FTIR spectroscopy. The changes induced by drug adsorption in the porous and fluorescent properties of zirconia particles were also examined. Additionally, as ursolic acid loaded particles proved to be stable in physiological medium, they were radiolabelled with technetium-99m ( 99m Tc) isotope. As labelling stability was excellent, normal biodistribution studies were performed in two healthy Beagle dogs using SPECT/CT imaging in order to prove in vivo particle size stability of NPs and verify the ability of the method to carry out prospective in vivo follow-up investigations of the drug delivery process.
Experimental section Materials
Absolute ethanol (a.r., >99.7%, < 0.2% water, Reanal), cesium chloride (CsCl, Specpure, trace metal basis); zirconium (IV) butoxide (TBOZ, 80 wt% in butanol, Sigma-Aldrich) were used for the optimized synthesis of ZrO 2 . TBOZ was kept and manipulated under argon gas. Cetyltrimethylammonium chloride (CTAB, ≥99%, Acros Organics) was used in preliminary experiments for the induction of fluorescence and porosity. Ultrapure water was collected from a MilliQ System. D,L-α-difluoromethylornithine called also eflornithine (DFMO or E ≥97%, Sigma), doxorubicin hydrochloride (DOX, 98.0%, Calbiochem) and ursolic acid (UA, ≥90%, Sigma-Aldrich) were used as received. Doxorubicin was kept in dark at 4°C. Methyl ethyl ketone (MEK, Reanal) was used for thin layer chromatography.
Preparation of zirconia particles
The synthesis route described by Widoniak et al. 20 was used with modifications. Briefly, a magnetic stirrer with oil bath, glassware, pipettes and reagents were put in a glove box. Freshly prepared 0.1 M CsCl solution was put in a scraw cap vial. 100 ml of abs. ethanol was poured into a 250 ml glass vial, stirred at 300 rpm with a triangle stir bar and heated to 60°C. The glove box was closed and flushed with argon. 0.4 ml CsCl solution was pipetted into the ethanol. After homogenization 3.25 ml of TBOZ was quickly added to it and the glass vial was closed. The solution became white within one minute. Next day the sol was centrifuged three times at 4000 rpm (10 min). The supernatant was discarded and the sediment resuspended in ethanol by means of an ultrasonic homogenizer (150VT, BioLogics) (solid content: 8.3 ± 0.8 mg/ml; mean and standard deviation of 3 parallel measurements). The product was kept at 4°C.
Drug adsorption

5×10
-6 mol DFMO (in powder), DOX (dissolved in 2.3 ml water)
and UA (dissolved in 3.8 ml ethanol) was added to 5 ml of ZrO 2 sol (64 mg ZrO 2 ). The mixtures were stirred (in dark for doxorubicin) for 3 days, and then they were centrifuged (4000 rpm, 18 min). The sediment was rinsed with 3 ml of water and centrifuged a second time. The particles were finally resuspended in 5 ml water. Samples with adsorbed drug were labelled ZE (DFMO), ZD (doxorubicin) and ZU (ursolic acid). The maximum drug encapsulation was determined adding 0.306 µmol drug in 2 ml ethanol to 300 µl ethanolic sol (2 mg of ZrO 2 ), stirring in dark for 3 days, centrifugation and analysis of the supernatant.
Characterization
Structure and morphology of zirconia particles. . X-rays were supplied by a GeniX 3D Cu ULD integrated beam delivery system (Xenocs SA, Sassenage, France). The highly monochromatic Cu K α radiation (0.15418 nm wavelength) was collimated by three pinholes of size 300, 300 and 400 μm diameter. A small amount of dry powder from each sample was fixed between two layers of scotch tape and mounted onto the standard sample holder. SAXS patterns were recorded by a Pilatus-300k CMOS hybrid pixel twodimensional position sensitive detector (Dectris Ltd, Baden, Switzerland) at two different sample-to-detector distances: 457 and 1218 mm, in order to cover a wide range in the scattering variable (q=4πsinθ/λ where 2θ is the scattering angle). The scattering patterns were corrected and calibrated using the on-line data reduction procedure implemented in the instrument control software. Subsequently, scattering patterns were azimuthally averaged, and the resulting onedimensional scattering curves were scaled together in intensity and merged, yielding for each sample a single scattering curve covering the whole experimentally attainable angular range. DLS measurements were carried out in a Malvern Zetasizer 
C Results and discussion
Structure and morphology of zirconia particles
The zirconia samples obtained in ethanol by controlled hydrolysis and condensation of zirconium (IV) butoxide possess a particle diameter over micrometer 19, 20 . The process is a multistep reaction as detailed by Widoniak et al. 20 : after hydrolysis of the metalorganic precursor small crystallites form, whose aggregation provides large secondary particles. The last reaction step is demonstrated by the whitening of the reaction mixture (usually within 1-5 min). According to our XRD and FTIR measurements, the small zirconia crystallites of 2.5 nm diameter are mainly crystallized in monoclinic structure (see diffractogram in Figure S-1 in ESI) . The TEM analysis of Cs + -doped ZrO 2 particles has evidenced particles with nearly 300-400 nm diameter (inset in Figure 1 ). The mean hydrodynamic diameter evaluated from number weighted size distribution function is 384 nm ± 80 nm (standard deviation) (Fig. 1) Ethanol mediated sol gave rise to nearly 100 nm diameter particles ( Fig. S-2(b) in ESI) . However, when we examined the porous structure of templated and non-templated ZrO 2 , we observed the same pattern on SAXS curves (see Fig. S-3 (a) in ESI) corresponding to micropores. As the elimination of CTAB molecule by washing is time-and solvent-wasting, nontemplated (Widoniak-type, with Cs + ions) synthesis was further used for the synthesis of microporous zirconia. The effect of annealing (400°C, 5h) has also been studied: the crystallite size of zirconia has increased to 65 nm, and the prevailing crystal structure became tetragonal (see diffractograms in Fig. S-4 in ESI). The annealed samples were found aggregated and SAXS curve did not show increased porosity (Fig. S-3(b) in ESI). The elimination of template molecules by annealing is therefore unfavourable for drug carrier particle synthesis. The scattering curve of the Widoniak-type zirconia powder sample shown in Fig. 2 .a starts with a power-law part, characteristic to the surface scattering of the aggregates of the primary ZrO 2 particles. A least-squares fit to the starting part of the curve revealed the power-law exponent to be -3.516 ± 0.008, which corresponds to 2.484 surface fractal dimension, reflecting that these larger entities are composed of the smaller, primary particles 36 . The power-law part is followed by a knee in the scattering pattern, turning later on into another power-law. This section of the scattering curve is characteristic to two-phase system formed by the primary particles and the pores between them, the curvature describing the average size, while the power-law carries information on the fractality. The corresponding parameters can be extracted from the curve by a least squares fit of an empirical, unified GuinierPorod model to this range 37 . According to this model we obtain 0.68 ± 0.06 nm for the radius of gyration, which corresponds to 1.76 nm ± 0.15 nm equivalent sphere diameter. The power-law exponent is -2.75 +/-0.03, and since its magnitude is less than 3, it corresponds to pore/mass fractal behaviour (instead of surface fractality), with a fractal exponent of 2.75 +/-0.03, describing the micropore structure. The fitting of the two parts of the scattering curves were done simultaneously, i.e. using the following function:
Here the first term corresponds to the starting power-law describing the surface scattering of the aggregates, and the second term is the unified Guinier-Porod model. In this model only the G scaling factor, the R g radius of gyration and the β second power-law exponent are the free parameters, because B and q* are determined from constraints of continuity in the function and its first derivative. The microporous structure of Widoniak-type zirconia was confirmed by N 2 adsorptiondesorption experiments (Fig. 2.b) . The BET surface area was 16 m 2 /g (the value of C parameter was 466) and the total volume of micropores was ~0.007 cm 3 /g, which are consistent with those found by Widoniak et al. 20 . The maximum of pore size distribution is at 1.52 nm, which is in very good agreement with the results found by SAXS. Interestingly, Widoniak et al. did not remark the microporous structure of the sample. Induction of fluorescence in zirconia particles. Several works have described rare earth doping-induced fluorescence in zirconia powders [38] [39] [40] [41] [42] [43] , but they dealt with di-and trivalent ions that prevent secondary particle formation in our case (experiments not shown). We therefore studied the method of Zhang et al. that describes fluorescence induced by CTAB residues after annealing 23 . We annealed a portion of CTABtemplated zirconia, resuspended the powder in ethanol, and compared its fluorescence to that of a Widoniak-type sol ( Fig   S-5 , similar solid contents were applied). In additional experiments (not shown), the fluorescence of several metalion mediated synthesis products was recorded (Pt 2+ , Pr 3+ , Ir 3+ ), but band positions were always the same. We propose therefore that organic residues (or metal ion impurities) are not the origin of zirconia fluorescence as published by Zhang et al.
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; this photoluminescence is an inherent characteristic of sol-gel derived zirconia particles, probably related to surface defects.
Drug adsorption studies
The fluorescent and microporous Widoniak-type zirconia was studied as a potential drug carrier particle. DFMO, DOX and UA were selected as carboxyl and/or amine bearing drug molecules (DFMO carries both functionalities) and adsorbed at the particle surface (samples denoted as ZE, ZD and ZU). The thermogravimetric analysis of dried samples permits to separate the weight loss caused by desorption of water from that caused by the degradation of drug molecules ( Fig. 3.a) . The maximum of drug loading measured from supernatants and the drug content of washed particles are presented in Table 2 . After drug loading, the quantity of adsorbed carbonate (both bicarbonate and monodentate carbonate) species has diminished. Characteristic IR bands of UA and DFMO become visible upon appropriate subtraction of the native zirconia spectrum from ZU and ZE spectra, respectively (Fig. S-6 in ESI). The subtraction is not possible in the case of DOX, because surface species have been transformed: the new bands at 1559, 1381 and 1350 cm -1 are assigned to bridged carbonate ( Fig. 3.b) . It is to note that the red doxorubicin solution turns immediately violet upon addition to zirconia suspension that suggests strong interactions between drug molecules and the inorganic surface (see UV-visible spectra in Fig S-7 in ESI) . In effect, the complexation between doxorubicin's chinoidal oxygens and neighbouring phenol groups has previously been described with Mn 2+ and Cu 2+ ions 45, 46 . We did not find, however, any previous mention of doxorubicin-Zr 4+ complex.
We carried out supplementary experiments on the basis of Abraham's work 45 . 100-200-300 mM ZrOCl 2 solutions were made in 100 mM HEPES buffer (pH 8), and DOX solution was added to each one and to pure HEPES buffer (86 µM final DOX concentration). In the presence of Zr 4+ ions, the solutions became immediately purple, the same as for native ZrO 2 particles transferred into HEPES from ethanol by centrifugation. However, when native ZrO 2 powder dried at 60°C was resuspended in HEPES, DOX did not turn purple upon addition. In this case the carbonate species at the zirconia surface did not change, as revealed by FTIR spectroscopy (see FTIR spectra in Fig. S-8 in ESI) . We assume that the surface area of zirconia is much reduced upon drying due to irreversible aggregation, and the number of surface defects providing complexation sites is also decreased in consequence.
The measurement of zeta potential as a function of pH is a sensitive method for the investigation of interactions at the surface of nanoparticles. The isoelectric point (IEP) of Widoniak-type zirconia is at pH 7.1 (Fig. 4) . This corresponds to the value (7.0-7.3) reported earlier for pure zirconia 47 . The IEP of ZD sample coincides with that of pure zirconia. At first sight it seems that DOX does not establish a direct interaction with zirconia surface. DFMO shifts slightly the IEP towards acidic region (pH 6.5). The largest shift corresponding to the highest affinity is observed for ursolic acid, where IEP becomes lower than pH 6. We also remarked that the surface charge at pH 7.5 (physiological) becomes lower than -20 mV due to UA adsorption which may provide colloidal stability for the intended drug carrier at this pH. These findings let us think that DFMO and UA adsorb directly at the metal oxide surface, while doxorubicin interacts in an indirect way. We examined the changes induced by drug adsorption in luminescent properties of zirconia suspension (Fig. 5.) . Fluorescence emission bands are not shifted upon drug adsorption, but their intensity vary significantly (the solid content of samples was identical). In the presence of doxorubicin, the emission intensity increases, while for the two other drugs it decreases. These results indicate that the mechanism of fluorescence does not change upon drug adsorption. The quantum efficiency is higher when doxorubicin is present. DOX may inhibit non-radiative recombination or can play the role of donor in fluorescence resonance energy transfer (FRET) mechanism. However, the latter can be excluded since the excitation of zirconia is effectuated at much lower wavelength (~274 nm) than the emission of doxorubicin (~600 nm) 48 . In the case of UA, the zirconia surface is supposed to transfer energy to the organic molecule, but the UV absorption of UA is below 200 nm, therefore FRET quenching cannot take place. It seems that UA is simply lowering the number of active sites by adsorbing at active Zr 4+ ions or eliminating carbonates interacting with active Zr 4+ ions, while DOX is decreasing the probability of nonradiative recombination by complexing coordinatively unsaturated (cus) Zr 4+ ions, or eventually by transforming surface carbonates into bridged carbonates. DFMO, on the other hand is supposed to quench the fluorescence of zirconia through FRET mechanism, since its highest wavelength UV absorption band is at 330 nm. Small-angle scattering curves of the loaded powder samples are presented in Fig. 6 . They have similar features as were seen in the case of the native zirconia sample, and the same mathematical models can be fitted. The results of the leastsquares fitting in the case of all four samples (including the native one) are summarized in Table S-1. The first difference between the loaded and native samples is the relative weight of the scattering from the primary particle/micropore system, related to the starting power-law. This can be characterized numerically by the B/A ratio (according to the notation in the fitting function in Experimental section). As seen from the table, this ratio is significantly smaller for the loaded powders. This is expected, as the absolute scattering weight of the pore system decreases as the electron density contrast between the pore and the ZrO 2 phases decreases, and the scattering contribution of the aggregates does not change much. This is also expressed in the fact that the first power-law exponents does not change significantly, thus the aggregates retain their surface fractal property. The radii of gyration determined from the micropore part do decrease, however, if only slightly. The most prominent change is found in the case of ZD, where the original, approx. 0.68 nm radius of gyration decreased to 0.56, corresponding to 1.44 nm equivalent sphere radius. This decrease in all of the loaded samples may also be attributed to the filling of the pores. It can be assumed that the filling substance form thicker, denser layers near the pore walls and contained more loosely in the lumina of the pores. Definition of surface structures. According to all our observations, we have constructed model structures for the interpretation of surface interactions of the three drug molecules studied (Fig. 7) . Here we present the most probable structures, whose presence have either been spectrally proven or suggested on the basis of FTIR and UV-visible spectroscopy, fluorimetry, zeta potential results and previous observations 9, 11, 13, 49 . Doxorubicin is proposed to complex cus Zr 4+ ions at the surface without dislocating them. The origin of luminescent property may also be cus Zr 4+ ions, but this hypothesis needs further investigation. Because of surface Zr 4+ complexation, the carbonate structure is changed, and bridged type of carbonate becomes dominant. The lack of change in the isoelectric point of ZrO 2 might be the result of an equimolar consumption and formation of surface negative charges (-O   - ). The amino groups of DOX may enter into electrostatic interactions with surface carbonate species, since these are in the ionic from according to FTIR shifts. DFMO and UA are mainly replacing surface carbonates by linking directly to basic sites, but are also supposed to be involved in H-bonds.
Radiolabeling and normal distribution study
As the zeta potential-pH measurement has shown that ZU sample may be stable under physiological conditions an aliquot of ZU suspension was centrifuged and the particles were suspended in 10 mM phosphate buffer (pH 7.5). DLS measurements proved that these particles maintained their dispersity over a period of 10 days at room temperature (Fig.  S-9 in ESI). Samples were thereafter radiolabelled. Tc-radiolabeling proved to be a simple and rapid procedure. Labeling efficiency was above 98% and excellent in vitro 99m Tcbinding stability could be observed. The normal biodistribution of the 99m Tc-ZU sample in two healthy beagle dogs is shown in High liver (44% and 48% of total injected activity) and urinary bladder uptakes were seen 30 min post i.v. applications. Moderate accumulations were recorded in the kidneys and negligible by the thyroids, heart and lungs. The results indicated that the size of injected nanoparticles is strictly lower than 1000 nm (because of very low detectable accumulation in the lungs) while NPs have a stable 99m Tc-binding capability (concluded from very low thyroid uptakes).
Conclusions
In conclusion, we have revealed that the synthetic method elaborated by Widoniak et al. 20 yielded inherently fluorescent and microporous zirconia particles that has not yet been remarked in the literature. We assume that the inherent fluorescence observed for colloidal ZrO 2 particles originates from surface defects (possibly coordinatively unsaturated Zr 4+ ions), whose number decreases upon aggregation, drying and annealing of the particles. Despite the great structural differences in their molecular structure, carboxyl-bearing DFMO and UA identically link to basic surface sites eliminating some of the surface carbonate species. We have evidenced that doxorubicin enters into strong complexation interaction with coordinatively unsaturated Zr 4+ species without moving them away from the surface (increased fluorescence) similarly to that observed for Mn 2+ ions 45 . This process perturbs, however, surface carbonate species and transforms them into bridged carbonate (band changes in FTIR spectra). The carrier particle retains its fluorescent property upon drug adsorption, and ursolic acid even stabilizes the particles at physiological pH. Preliminary radiolabeling and follow-up probes verified that the method is able to carry out prospective SPECT/CT drug delivery follow-up studies with the 99m Tc-labelled ursolic acid-capped zirconia. The use of such zirconia particles seems particularly interesting in the future for topical radiotherapy with β-emitting isotopes that induce fast degradation in polymeric nanocarriers.
